M2Bio Sciences Partnership with EFC Delivers Jaw-Dropping Statistics

Home » blog » M2Bio Sciences Partnership with EFC Delivers Jaw-Dropping Statistics
M2Bio Sciences Partnership with EFC Delivers Jaw-Dropping Statistics

EFC 2022 Stats

Institute of Biomedical Research (OTCBB:MRES)

CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, January 19, 2023 /EINPresswire.com/ — Institute of Biomedical Research (OTC PINK: MRES) (“M2Bio Sciences” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following mind-blowing update:

M2Bio is pleased to announce that the EFC platform has returned striking Facebook data analytics for 2022. In 2023 it is anticipated that these numbers will be greatly surpassed as plans for EFC global expansion are put into place and executed upon.

In 2022, the EFC blew through all African online records and its own previous Facebook engagement, reach and video view statistics – by reaching into the billions. EFC’s unique history in African sport and entertainment has proven yet again, there is nothing else on the continent even remotely close to the EFC in terms of Facebook audience and engagement.

EFC President Cairo Howarth – “These astounding figures tell a story we’ve known for some time about our value chain. The record-breaking platform we place our athletes on, the exposure we’re able to provide to our loyal partners and the quality content consumed by the best fans in the world. No other sporting entity on the continent is able to provide that kind of value and in that regard, 2023 is already shaping-up to be our best year yet!”

M2Bio Sciences CEO Jeff Robinson – “We are stoked to continue bringing serious science, medicine and technology to the EFC. Our partnership is really something out of this world so you better fasten your seatbelts for 2023 because we’re headed for Uranus! ”

About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “MRES”.
Publicly traded company (OTC Pink:MRES)

Website: www.m2bio.co
E-mail: info@m2bio.co

Forward-Looking Statements:
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Jeff Robinson
M2Bio Sciences Food and Beverage (Pty) Ltd
+27 72 333 2148
email us here

You just read:

News Provided By

January 19, 2023, 13:25 GMT

EIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone’s Internet News Presswire™, tries to define some of the boundaries that are reasonable in today’s world. Please see our Editorial Guidelines for more information.